This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.
Christina Vanhinsbergh
Advertisement
Christina Vanhinsbergh is New Modalities Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.
Articles by Christina Vanhinsbergh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5